SHANGHAI, Jan 27 (Reuters) - German drugmaker Boehringer Ingelheim will license an experimental inflammatory bowel disease ...
Halo Pharma becomes a standalone drug product CDMO after the sale of Noramco’s API assets, adding sterile services by H2 2026 ...
SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland)The ...
AI: How does this technological revolution fit with the pharmaceutical regulators who oversee the pharmaceutical sector at ...
India Education Diary (English) on MSN
Union Health Ministry Notifies Key Amendments to NDCT Rules, 2019 to Reduce Regulatory Burden and Promote Ease of Doing Business
India, Jan. 28 -- Union Ministry of Health and Family Welfare has notified key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, in line with the directions of Hon'ble Prime Minister ...
Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, ...
Insilico Medicine and Qilu Pharmaceutical Group announced a strategic collaboration to jointly develop small-molecule inhibitors for cardiometabolic diseases, combining Insilico’s generative AI–driven ...
Jan 29 (Reuters) - Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on ...
Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, ...
Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.
HANGZHOU, ZHEJIANG, CHINA, January 16, 2026 /EINPresswire.com/ -- The pharmaceutical industry is undergoing a period of ...
Chinese drugmaker Qilu Pharmaceutical will be responsible for developing metabolic disease drug candidates from Insilico Medicine under a contract with a total value that "approaches" $120 million, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results